Additional information
| Active substance | Empagliflozin |
|---|---|
| Chemical name | (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol |
| Side effects | Urinary tract infections, genital infections, increased urination, dehydration, hypotension |
| Effects | Lowers blood sugar levels, aids in weight loss, and reduces blood pressure and cardiovascular risks |
| Dosage (sports) | Not applicable as it is not used for enhancing athletic performance |
| Dosage (medical) | Typically 10 mg once daily, may be increased to 25 mg based on patient's condition and response |
| Half-life | Approximately 12.4 hours |
| Main action | Reduces blood glucose by inhibiting glucose reabsorption in the kidney |
| Substance class | Sodium-glucose co-transporter 2 (SGLT2) inhibitor |
| Formula | C23H27ClO7 |
| Storage conditions | Store at room temperature, away from moisture and heat |
| Trade name | Jardiance |
| Blood pressure | Can cause a modest reduction in blood pressure |
| Also known as | Empa |
| Strength | 10mg |
| Lab Test | Monitoring of renal function and blood glucose levels |
| Hepatotoxicity | Low risk |
| Water Retention | Can lead to a reduction in overall body water content |
| Use in sports | Not typically used in sports due to its mechanism focused on lowering blood glucose levels |
| Manufacturer | Boehringer Ingelheim Pvt. Ltd. |
| Packing | 10 tabs/blister |
Reviews
There are no reviews yet.